Biologics Regulatory Doron Therapeutics Announces First Patients Dosed in Phase 3 Study of MOTYS (PTP-001) for the Treatment of Osteoarthritis of the Knee byTim AllenOctober 17, 2025
Spine Top Stories RevBio Receives a $2.2 Million Phase II NIH Grant to Further Develop the Minimally Invasive Use of TETRANITE® to Treat Complex Spine Fractures byTim AllenOctober 6, 2025
Regulatory U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor byNoah SimmonsSeptember 29, 2025
Regulatory Top Stories CurvaFix Secures FDA Clearance to Advance Pelvic Fracture Treatment byTim AllenSeptember 3, 2025
Financial Spine Degenerative Disc Disease Treatment Market is Expected to Reach Revenue of USD 66.2 Bn by 2033, at 7.7% CAGR: Dimension Market Research byTim AllenOctober 8, 2024
Spine Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans byJosh SandbergAugust 21, 2024
Spine New4med GmbH Announces First Cases of its novel Basivertebral Nerve Ablation (BVNA) byTim AllenJuly 8, 2024
Spine Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain byTim AllenApril 25, 2024
Recon Hyalex Orthopaedics Reports Treatment of First Patients with Novel HYALEX® Knee Cartilage System byJosh SandbergApril 22, 2024
Recon Regulatory Top Stories Lipogems Announces First Patient Enrolled in the Second U.S. FDA IDE Study for the Treatment of Knee Osteoarthritis byTim AllenApril 8, 2024
